Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors.

Aggregates Dextran sulfate Expansion Fed-batch Human induced pluripotent stem cells Single-use bioreactors Vertical-Wheel bioreactors

Journal

Journal of biological engineering
ISSN: 1754-1611
Titre abrégé: J Biol Eng
Pays: England
ID NLM: 101306640

Informations de publication

Date de publication:
2019
Historique:
received: 12 06 2019
accepted: 04 09 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 20 9 2019
Statut: epublish

Résumé

Since their inception, human induced pluripotent stem cells (hiPSCs) have held much promise for pharmacological applications and cell-based therapies. However, their potential can only be realised if large numbers of cells can be produced reproducibly on-demand. While bioreactors are ideal systems for this task, due to providing agitation and control of the culture parameters, the common impeller geometries were not designed for the expansion of mammalian cells, potentially leading to sub-optimal results. This work reports for the first time the usage of the novel Vertical-Wheel single-use bioreactors for the expansion of hiPSCs as floating aggregates. Cultures were performed in the PBS MINI 0.1 bioreactor with 60 mL of working volume. Two different culture media were tested, mTeSR1 and mTeSR3D, in a repeated batch or fed-batch mode, respectively, as well as dextran sulfate (DS) supplementation. mTeSR3D was shown to sustain hiPSC expansion, although with lower maximum cell density than mTeSR1. Dextran sulfate supplementation led to an increase in 97 and 106% in maximum cell number when using mTeSR1 or mTeSR3D, respectively. For supplemented media, mTeSR1 + DS allowed for a higher cell density to be obtained with one less day of culture. A maximum cell density of (2.3 ± 0.2) × 10 The results here described present the Vertical-Wheel bioreactor as a promising technology for hiPSC bioprocessing. The specific characteristics of this bioreactor, namely in terms of the innovative agitation mechanism, can make it an important system in the development of hiPSC-derived products under current Good Manufacturing Practices.

Sections du résumé

BACKGROUND BACKGROUND
Since their inception, human induced pluripotent stem cells (hiPSCs) have held much promise for pharmacological applications and cell-based therapies. However, their potential can only be realised if large numbers of cells can be produced reproducibly on-demand. While bioreactors are ideal systems for this task, due to providing agitation and control of the culture parameters, the common impeller geometries were not designed for the expansion of mammalian cells, potentially leading to sub-optimal results.
RESULTS RESULTS
This work reports for the first time the usage of the novel Vertical-Wheel single-use bioreactors for the expansion of hiPSCs as floating aggregates. Cultures were performed in the PBS MINI 0.1 bioreactor with 60 mL of working volume. Two different culture media were tested, mTeSR1 and mTeSR3D, in a repeated batch or fed-batch mode, respectively, as well as dextran sulfate (DS) supplementation. mTeSR3D was shown to sustain hiPSC expansion, although with lower maximum cell density than mTeSR1. Dextran sulfate supplementation led to an increase in 97 and 106% in maximum cell number when using mTeSR1 or mTeSR3D, respectively. For supplemented media, mTeSR1 + DS allowed for a higher cell density to be obtained with one less day of culture. A maximum cell density of (2.3 ± 0.2) × 10
CONCLUSIONS CONCLUSIONS
The results here described present the Vertical-Wheel bioreactor as a promising technology for hiPSC bioprocessing. The specific characteristics of this bioreactor, namely in terms of the innovative agitation mechanism, can make it an important system in the development of hiPSC-derived products under current Good Manufacturing Practices.

Identifiants

pubmed: 31534477
doi: 10.1186/s13036-019-0204-1
pii: 204
pmc: PMC6744632
doi:

Types de publication

Journal Article

Langues

eng

Pagination

74

Déclaration de conflit d'intérêts

Competing interestsAuthors YH and RW are employees of PBS Biotech. The author BL is CEO and co-founder of PBS Biotech, Inc. These collaborating authors participated in the development of the bioreactors used in the manuscript. This does not alter the authors’ adherence to all the policies of the journal on sharing data and materials. All other authors declare no conflict of interest.

Références

Biotechnol Prog. 2000 May-Jun;16(3):319-25
pubmed: 10835230
Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):103-13
pubmed: 11947941
Biotechnol Bioeng. 2005 May 20;90(4):452-61
pubmed: 15778986
Nat Biotechnol. 2006 Feb;24(2):185-7
pubmed: 16388305
Nat Methods. 2006 Aug;3(8):637-46
pubmed: 16862139
Science. 2007 Dec 21;318(5858):1917-20
pubmed: 18029452
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Biotechnol Bioeng. 1997 May 5;54(3):191-205
pubmed: 18634086
Nat Biotechnol. 2009 Mar;27(3):275-80
pubmed: 19252484
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Adv Biochem Eng Biotechnol. 2009;114:201-35
pubmed: 19513633
Tissue Eng Part C Methods. 2010 Aug;16(4):573-82
pubmed: 19737071
Stem Cell Res. 2010 May;4(3):165-79
pubmed: 20363202
Stem Cells Dev. 2010 Nov;19(11):1781-92
pubmed: 20380517
Nature. 2011 Mar 10;471(7337):225-9
pubmed: 21240260
PLoS One. 2011;6(6):e20914
pubmed: 21698063
Biotechnol Adv. 2011 Nov-Dec;29(6):815-29
pubmed: 21726624
Biotechnol Appl Biochem. 2011 Jul-Aug;58(4):231-42
pubmed: 21838797
Stem Cell Res. 2012 May;8(3):388-402
pubmed: 22459095
Trends Biotechnol. 2012 Jun;30(6):350-9
pubmed: 22541338
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1848-57
pubmed: 22645348
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nat Protoc. 2012 Nov;7(11):2029-40
pubmed: 23099485
Nat Protoc. 2013 Jan;8(1):162-75
pubmed: 23257984
Tissue Eng Part C Methods. 2014 Jan;20(1):76-89
pubmed: 23668683
Stem Cell Res. 2013 Nov;11(3):1103-16
pubmed: 23973800
PLoS One. 2014 Jul 17;9(7):e102486
pubmed: 25032842
Biotechnol J. 2015 Oct;10(10):1578-88
pubmed: 26123315
Biotechnol Prog. 2015 Nov-Dec;31(6):1600-12
pubmed: 26289142
Biotechnol Prog. 2016 Sep;32(5):1113-1122
pubmed: 27114230
J Am Coll Cardiol. 2016 May 10;67(18):2161-2176
pubmed: 27151349
Stem Cells Transl Med. 2016 Oct;5(10):1289-1301
pubmed: 27369897
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
J Biosci Bioeng. 2018 Jan;125(1):111-115
pubmed: 28864123
BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Biotechnol Bioeng. 2018 Aug;115(8):2061-2066
pubmed: 29679475
Biochem Eng J. 2018 Mar 15;131:39-46
pubmed: 29736144
Nat Rev Genet. 2019 Jul;20(7):377-388
pubmed: 30737492
Biotechnol J. 2019 Aug;14(8):e1800716
pubmed: 30945467

Auteurs

Diogo E S Nogueira (DES)

1Department of Bioengineering and iBB, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
2The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Carlos A V Rodrigues (CAV)

1Department of Bioengineering and iBB, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
2The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Marta S Carvalho (MS)

1Department of Bioengineering and iBB, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
2The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Cláudia C Miranda (CC)

1Department of Bioengineering and iBB, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
2The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Yas Hashimura (Y)

PBS Biotech, Camarillo, CA USA.

Sunghoon Jung (S)

PBS Biotech, Camarillo, CA USA.

Brian Lee (B)

PBS Biotech, Camarillo, CA USA.

Joaquim M S Cabral (JMS)

1Department of Bioengineering and iBB, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
2The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.

Classifications MeSH